Pfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…
tofacitinib
1 article